SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Professor Bruce Neal introduce the Salt Substitute and Stroke Study, which defines the overall balance of benefits and risks of salt substitutes compared with  salt in terms of cardiovascular disease, including strokes and mortality.

2021 ESC Guidelines - CVD Prevention

Prof. Frank Visseren speaks about the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

The current management of Angina

Prof. Marzilli speaks about the current management of Angina.

LOOP Study: screening for AF with an implantable loop recorder to prevent stroke

This study looks at whether continuous ECG monitoring using an implantable loop recorder to detect atrial fibrillation – and subsequent anticoagulation if AF is detected – will reduce the risk of stroke or systemic arterial embolism in patients at risk.

TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest

This study examined whether immediate coronary angiography in survivors of out-of-hospital cardiac arrest and no ST-segment elevation is beneficial with regard to all-cause mortality at 30 days, compared with initial intensive care assessment with delayed/selective angiography.

ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation

Prof. Dangas  speaks about the outcomes of the ENVISAGE-TAVI AF trial.

2021 ESC Guidelines - Cardiac Pacing

Prof.  Glikson speaks about the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy.

The STEP Study

Prof.  Grobbee speaks about intensive vs. standard blood pressure control among older hypertensive patients.

The new advancements in angina

Prof. Gowdak speaks about the newest advnacements in the treatement of angina.

The RIPCORD 2 trial

Prof. Curzen speaks about the RIPCORD 2 trial. Does routine pressure wire assessment influence management strategy of coronary angiography for diagnosis of chest pain?

The EMPEROR-Preserved Trial

Prof. Anker speaks about the effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes.

The SMART-MI Trial

Prof. Bauer speaks about the SMART-MI-ICMs, implantable cardiac monitors in high-risk, postinfarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction.

2021 ESC Guidelines - Heart Failure

Prof. Metra speaks about the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

What is new about Angina?

Prof. Jankowski speaks about the current management of Angina.

2021 ESC Guidelines - Cardiac Pacing

Prof.  Nielsen speaks about the 2021 ESC Guidelines on cardiac pacing and cardiac resynchronisation therapy.

The APAF-CRT Trial

Prof. Brignole  speaks about the APAF-CRT Trial, AV junction ablation and CRT in patients with permanent atrial fibrillation and narrow QRS.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention